Aside from the coronavirus, moneypox is apparently making the rounds.
“Doctors warned that numbers will rise significantly as the virus spreads through Europe and as far as the US, Canada and Australia. Spain now has the highest number of infections, outside places in Africa where the virus is endemic, with more than 50 known cases.”
Now we’re learning that monkeypox cases just doubled in New York City.
“As of Monday, July 11, 223 people in the city have tested positive for orthopoxvirus and all likely have monkeypox, according to the city’s Health Department. That is up from 111 cases on July 5 and more than quadruple the number from a week prior to that,” says Fox5NY.com.
So, how can we potentially profit from it?
Emergent Biosolutions (EBS)
Emergent Biosolutions produces the ACAM2000 vaccine, which the US FDA describes as an active immunization against smallpox for those at higher risk. “According to the Centers for Disease Control and Prevention, since the monkeypox virus is closely related to the virus that causes smallpox, ACAM2000 can be used to prevent the spread of monkeypox,” says Barron’s.
SIGA Technologies (SIGA)
SIGA Technologies has been on the move on the virus news.
SIGA Technologies, Inc. announced approximately $13 million of procurement orders for oral TPOXX (tecovirimat), including $11 million for initial procurement from two new international jurisdictions and an approximate $2 million order from a country in the Asia Pacific region that has an established contract for oral TPOXX (tecovirimat).
Bavarian Nordic (BAVA)
Bavarian Nordic makes the only monkeypox vaccine that’s approved by the U.S.
According to FiercePharma.com:
Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases. The vaccine is approved under the brand name Jynneos in the U.S. with a label that also specifically covers monkeypox.